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Abstract: The fms-like tyrosine kinase 3 (Flt3) is a cell surface receptor that is expressed by various
hematopoietic progenitor cells (HPC) and Flt3-activating mutations are commonly present in acute
myeloid and lymphoid leukemias. These findings underscore the importance of Flt3 to steady-state
and malignant hematopoiesis. In this study, the expression of Flt3 protein and Flt3 mRNA by single
cells within the hematopoietic stem cell (HSC) and HPC bone marrow compartments of C57/BL6
mice was investigated using flow cytometry and the quantitative reverse transcription polymerase
chain reaction. Flt3 was heterogeneously expressed by almost all of the populations studied, including
long-term reconstituting HSC and short-term reconstituting HSC. The erythropoietin receptor (EpoR)
and macrophage colony-stimulating factor receptor (M-CSFR) were also found to be heterogeneously
expressed within the multipotent cell compartments. Co-expression of the mRNAs encoding Flt3 and
EpoR rarely occurred within these compartments. Expression of both Flt3 and M-CSFR protein at the
surface of single cells was more commonly observed. These results emphasize the heterogeneous
nature of HSC and HPC and the new sub-populations identified are important to understanding the
origin and heterogeneity of the acute myeloid leukemias.
Keywords: Flt3; growth factor receptors; cytokines; HSC; hematopoiesis; leukemia
1. Introduction
The hematopoietic stem and progenitor cells (HSPC) that give rise to all of the blood and immune
cell types are within a small fraction of bone marrow cells that lack lineage markers (Lin−) and express
Sca-1 and c-kit (LSK). HSPC are heterogeneous and multi-color flow cytometry has greatly aided the
sub-fractionation of the LSK compartment, for example, on the basis of CD34 expression [1]. However,
how to best phenotypically delineate populations of HSPC with differing biological properties is,
as yet, uncertain.
A marker that is used to sub-divide LSK is the cell surface receptor fms-like tyrosine kinase 3
(Flt3/Flk2) which is a class III tyrosine kinase with structural homology to the c-kit and macrophage
colony-stimulating factor (M-CSF/CSF1) receptors [2,3]. Flt3 was first identified on murine
hematopoietic progenitor cells (HPC) [3] while expression in humans is restricted to CD34+ bone
marrow cells, which include hematopoietic stem cells (HSC) [4]. Within the LSK compartment, only the
Flt3− fraction is capable of long-term myeloid reconstitution which has led to the viewpoint that Flt3
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expression is linked to a loss of self-renewal capacity [5–7]. The promoter region of the Flt3 gene (Flt3)
in Flt3− LSK cells is occupied in a primed state [8] and the use of Flt3-Cre:loxp-eYFP mice has revealed
that Flt3 expression occurs within a phenotypically defined HSC compartment [9]. However, when
LSK eYFP+ and eYFP− cells from Flt3-Cre: loxp-eYFP mice are transplanted into secondary recipients
only the latter provide robust myeloid reconstitution [9]. Boyer and colleagues have confirmed that all
hematopoietic cells develop from HSC via a Flt3+ progenitor [10]. Together, the above results provide
strong evidence to support the viewpoint that Flt3 protein can be first detected at the multipotent
progenitor (MPP) stage during murine hematopoiesis. However, Flt3 may be expressed at a low level
during earlier developmental stages and it remains unknown whether such expression might mark
functionally distinct HSPC.
Dimerization of Flt3 occurs upon binding of its ligand (Flt3L) resulting in auto-phosphorylation of
tyrosine residues [11,12], recruitment of the adapter proteins SHC, CBL and GRB [13–15] and signaling
via the phosphoinositide 3 kinase (PI3K) and RAS pathways [16,17]. PI3K signaling is important to cell
survival and, accordingly, the ligand promotes the survival and growth of hematopoietic progenitors,
particularly myeloid and B lymphoid pathway progenitors [18–20]. The use of semi-solid medium
assays has revealed that Flt3L influences the formation of granulocyte-macrophage (GM) colonies by
human bone marrow CD34+ cells [21]. Flt3L also synergizes with other cytokines. The addition of Flt3L
to interleukin (IL)-3 or IL-6 doubles the cell number in the colonies derived from mouse Lin− Thylo
Sca-1+ bone marrow cells and FltL combined with IL-3 or granulocyte-macrophage colony-stimulating
factor (GM-CSF) enhances the growth of Lin− CD34+ CD33+ human fetal liver progenitor cells [22].
Flt3L alone has little or no effect on these populations [19,23–26]. Flt3L has also been shown to
synergize with the GM-CSF-IL-3 fusion protein Pixy 321 for human HPC [21] and with stem cell
factor, GM-CSF, IL-6, IL-7, IL-11 and IL-12 for both murine and human HPC [23–30]. Importantly,
Flt3L alone or combined with other appropriate cytokines does not affect the growth of the erythroid
(BFU-E and CFU-E) [23,26,28] or megakaryocyte colonies in vitro [25,31,32]. In essence, the range of
action of Flt3 is restricted to cells belonging to the lymphoid and GM pathways.
Flt3L−/− mice have a reduced bone marrow, spleen and lymph node cellularity, and decreased
numbers of dendritic cells (DC), Gr-1+ CD11b+ myeloid cells and lymphoid cells, including innate
lymphoid cells [33,34]. Injection of Flt3L into mice leads to leukocytosis which is mostly due to
an elevation in monocytes. The absolute number of LSK in bone marrow, spleen and peripheral blood
is increased, lymphocytes are elevated, and there is a significant decrease in the hematocrit value and
a 90% reduction in immature TER119+ erythroid cells [35]. Ceredig and colleagues injected mice with
Flt3L and observed a 50% expansion of Flt3+ CD19− B220+ CD117lo cells, termed Early Progenitors with
Lymphoid and Myeloid potential, and an increase in the number of DC [36,37]. Similarly, transgenic
mice that express supra-physiological levels of human Flt3L (Flt3L-Tg) have increased numbers of
Gr-1+ CD11b+ myeloid cells, NK1.1+ cells and DC. Studies of Flt3L-Tg mice have led to the proposition
that Flt3L above a certain threshold level instructs myeloid and lymphoid development at the expense
of cells developing along the megakaryocytic and erythroid (MegE) pathways, as these mice are
anemic, thrombocytopenic and have a 9.7-fold decrease in megakaryocyte-erythrocyte progenitors
(MEP) [38].
Blast cells of most cases of acute myeloid leukemia (AML) express Flt3 [39,40] and Flt3L has
a strong stimulatory effect on these cells, enhancing colony growth when other cytokines are present
at suboptimal levels [41]. Furthermore, around 35% of AML patients harbor a FLT3 mutation [42,43],
which often leads to constitutive activation of Flt3. In frame internal tandem duplications (ITD), in
the juxta-membrane part of Flt3, account for 25–35% of the mutations in AML [44] and 5–10% of
myelodysplastic syndrome (MDS) cases [45,46]. FLT3-ITD has also been associated with malignant
transformation of MDS [45,47] and a poor prognostic outcome in AML [42,44,48–50], with the ratio
of mutant to wild-type alleles having an impact [51]. The second most common FLT3 mutations are
missense point mutations in the tyrosine kinase domain which occur in approximately 5–10% of AML,
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2–5% of MDS and 1–3% of acute lymphocytic leukemia (ALL) cases [46,51,52]. As to all of the above,
selective Flt3 inhibitors are being examined as a means of treating some cases of AML [44,53].
Various populations of murine HSPC can be isolated by the use of cell surface markers,
for example, the signaling lymphocytic activation molecule family of markers CD48, CD150 and
CD224 [54]. In this study, we have used a combination of the quantitative reverse transcription
polymerase chain reaction (qRT-PCR), to examine mRNA within single cells, and flow cytometry,
for protein expression, to delineate the extent sub-populations of HSPC express Flt3. The expression
of Flt3, or not, has been examined in relation to the expression of the receptors for erythropoietin
(Epo) and M-CSF. The use of a triplex qRT-PCR assay and multi-color flow cytometry has revealed
substantial heterogeneity of HSPC.
2. Results
2.1. Heterogeneous Expression of Flt3 Transcripts by Single HSPC
Cell surface phenotypes that had been adapted from published profiles were used to identify and
isolate the various populations of HSPC from murine bone marrow (Figure 1). The LSK compartment
was divided into HSC (LSK CD150+ CD48−), MPP (LSK CD150− CD48−), HPC-1 (LSK CD150−
CD48+) and HPC-2 (LSK CD150+ CD48+), as published by the Morrison group [54,55]. HSC were
divided into LT-HSC (LSK CD150+ CD48− CD34−) or ST-HSC (LSK CD150+ CD48− CD34+) based
on their expression of CD34 [1]. The gating strategy used to identify HPC-1 is similar to the one
used by Adolfsson et al. to identify lymphoid-primed multipotent progenitors (LMPP), as these two
cell populations express high levels of Flt3 at their surface [55,56]. Therefore, HPC-1 were divided
into Flt3−/lo HPC-1 (LSK CD150− CD48+ Flt3−/lo) and Flt3hi LMPP (LSK CD150− CD48+ Flt3hi).
The common myeloid progenitors (CMP; LS−K IL-7Rα− CD16/32lo CD34hi), granulocyte-macrophage
progenitors (GMP; LS−K IL-7R− CD16/32hi CD34hi), MEP (LS−K IL-7Rα− CD16/32lo CD34lo) and
common lymphoid progenitors (CLP; LSintKint IL-7R+) were identified according to the strategies
published by the Weissman group [57,58].
First, expression of Flt3 mRNA by single cells within each of the above populations was
investigated using qRT-PCR (Figure 2). Cells that expressed Flt3 mRNA (Flt3mRNA+) and the
endogenous control mRNA, Actb, could be readily identified (Figure 2A,B). In total, 1465 single
cells were sorted and Actb mRNA was detected in 1416 samples (96.7%). Samples that did not contain
detectable levels of Actb mRNA were removed from analysis.
Within the LT-HSC compartment, 11.6 ± 2.19% of cells (28 of 248 cells) expressed a detectable
level of Flt3 mRNA (Figure 2C,D). Flt3 mRNA was expressed by 21 ± 3.4% (56 of 252 cells) of ST-HSC,
which was significantly higher than the percentage of Flt3mRNA+ LT-HSC (p = 0.0476) (Figure 2C,D).
Two hundred ninety-seven MPP were analyzed and 64± 2.2% (190 cells) of these cells were Flt3mRNA+
(Figure 2C,D). Analysis of progenitors that are associated with the myeloid pathways revealed a clear
decrease in the percentage of Flt3mRNA+ cells as compared to the percentage of Flt3mRNA+ MPP
(Figure 2C,D). Eighty-one CMP were analyzed and 21 of these cells expressed Flt3 mRNA (24.9± 5.4%).
Similarly, 21.4± 2.8% (21 of 98 cells) and 9.9± 6.0% (8 of 56 cells) of GMP and HPC-2 were Flt3mRNA+,
respectively. Only one of the 98 MEP assayed (1± 1%) was found to be Flt3mRNA+. On the other hand,
the fractions of Flt3mRNA+ cells within the lymphoid pathway-associated progenitor compartments
were either comparable or greater than the percentage of Flt3mRNA+ cells within the MPP population
(Figure 2C,D). Within the LMPP population, 92.8 ± 2.0 of cells (90 of 97 cells) were Flt3mRNA+,
while 57.2 ± 14.1% (57 of 101 cells) and 66.2 ± 3.8% (62 of 94 cells) of Flt3−/lo HPC-1 and CLP were
Flt3mRNA+, respectively. Together, these data demonstrate that Flt3 mRNA is expressed by cells
within almost all HSPC populations, including HSC.
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Figure 1. Isolation of hematopoietic stem and progenitor cells (HSPC) from mouse bone marrow.
The gating strategies used to identify hematopoietic stem cells (HSC) and various progenitors are
shown. The areas delineated by the black boxes in the scatter plots and solid black lines in the
histograms indicate the population of cells gated. Dashed arrows point to further gating of these cells.
Shaded areas in the histograms depict the isotype control staining. Lineage markers (Lin) included
CD3ε, B220, CD11b, Ly-6G and TER-119. HSPC, hematopoietic stem and progenitor cells; LT-HSC,
long-term reconstituting hematopoietic stem cell; ST-HSC, short-term reconstituting hematopoietic
stem cell; HSC, hematopoietic stem cell; MPP, multipotent progenitor; HPC, hematopoietic
progenitor cell; lymphoid-primed multipotent progenitors (LMPP), lymphoid-primed multipotent
progenitor; common lymphoid progenitors (CLP), common lymphoid progenitor; common myeloid
progenitors (CMP), common myeloid progenitor; GMP, granulocyte-macrophage progenitor; MEP,
megakaryocyte-erythrocyte progenitor; LS−K, Lineage marker− Sca1− c-Kit+; LSK, Lineage marker−
Sca1+ c-Kit+; Flt3, fms-like tyrosine kinase 3; IL-7R, interleukin-7 receptor. SSC, side light scatter; FSC,
forward light scatter.
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contained either comparable or greater percentages of Flt3+ cells as compared to the MPP population. 
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Figure 2. Expression of Flt3 mRNA transcripts by HSPC. Analysis of Flt3 mRNA expression by HSPC
was carried out using duplex qRT-PCR assays specific for both Actb and Flt3 transcripts. Reactions
that did not give rise to a detectable amplification of Actb were removed from analysis. Representative
amplification of: (A) the endogenous control mRNA, Actb; and (B) Flt3 mRNA in single HSC are
shown, where there is a clear distinction between cells that expressed the target gene (shown in red)
and those that did not (shown in green); (C) The percentage of cells within each HSPC population
that expressed Flt3 mRNA; and (D) the levels of Flt3 mRNA expressed by single HSPC. Flt3 mRNA
expression was estimated using the cycle at which the PCR signal crossed an arbitrary threshold
(Ct) and each individual cell is represented by a single data point. Single cells that gave rise to
a detectable amplification of Actb mRNA, but not Flt3 mRNA, are plotted below the dotted lines.
Data in (C,D) are the mean of the values obtained from n = 3–6 mice. In total, 248 LT-HSC, 252 ST-HSC,
297 MPP, 101 Flt3−/lo HPC-1, 97 LMPP, 56 HPC-2, 94 CLP, 81 CMP, 98 GMP and 98 MEP were
analyzed. p values were obtained by two-tailed non-parametric Student’s t-test, where * p < 0.05;
** p < 0.005,. HSC, hematopoietic stem cell; LT-HSC, long-term reconstituting hematopoietic stem
cell; ST-HSC, short-term reconstituting hematopoietic stem cell; MPP, multipotent progenitor; LMPP,
lymphoid-primed multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid
progenitor; GMP, granulocyte-monocyte progenitor; MEP, megakaryocyte-erythrocyte progenitor; Flt3,
fms-like tyrosine kinase 3; HSPC, hematopoietic stem and progenitor cell.
2.2. Expression of Flt3 Protein by HSPC Populations
Next, the expression of Flt3 protein on the surface of bone marrow HSPC was investigated by flow
cytometry (Figure 3). Flt3 protein was detected on the surface of 4.6 ± 1% of LT-HSC and 7.7 ± 1.2% of
ST-HSC (Figure 3A,B). Interestingly, the expression of Flt3 protein by HSC correlated with the presence
of a low level of CD150 at the cell surface (Figure 3D,E). A low level of expression of CD150 is associated
with a reduced potential for self-renewal, and MegE development [59,60]. Within the MPP population,
63.7 ± 3% of cells had detectable levels of Flt3 at their cell surface (Figure 3A,B). In agreement with
the gene expression analysis, the percentages of Flt3+ cells within the myeloid pathway-associated
progenitor populations were less as compared to the MPP compartment (Figure 3A). Flt3 was detected
on the surface of 36.8± 1.4% of CMP (Figure 3A,B). Within the HPC-2 and GMP populations, 9.3± 1.1%
and 15.7 ± 0.9% of cells were Flt3+, respectively (Figure 3A). Flt3 was virtually absent from the MEP
compartment (0.5 ± 0.06%) (Figure 3A). Lymphoid pathway-associated progenitor compartments
contained either comparable or greater percentages of Flt3+ cells as compared to the MPP population.
Flt3 was detected on the surface of 80 ± 2.1% of CLP, and 58.6 ± 3% of Flt3−/lo HPC-1 (Figure 3A,B).
Int. J. Mol. Sci. 2017, 18, 1037 6 of 19
As to their designated phenotype, 100% of LMPP were Flt3+ (Figure 3A). Similar to the Flt3 mRNA
expression data, these results show that Flt3 protein is expressed by all HSPC populations, apart from
MEP, and is most commonly found on the surface of HPC with robust lymphoid potential.
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Figure 3. Cell surface expression of Flt3 protein by HSPC: (A) the gating strategy used to detect
Flt3 on the surface of HSC and HPC populations (solid black line), compared to an isotype control
(shaded histogram); (B) the percentage of cells within each HSPC compartment that expressed Flt3
protein at their surface; (C) the gating strategy used to identify LSK CD48− cells with high (CD150hi)
and low levels of CD150 (CD150lo) expressed at their surface and those lacking CD150 expression
(MPP); (D) the percentages of Flt3+ and Flt3− cells within the HSC compartment that express low and
high levels of CD150 on their surface; and (E) the gating strategy in (C) applied to cells within the
Flt3+ and Flt3− HSC populations in a representative sample. Data in (A,B) and (C,D) are the mean of
the values obtained from n = 3–6 and n = 6 mice, respectively. Values depicted in (A,C,E) represent
the percentage of cells within each gate. Solid arrows in (A,C,E) indicate increasing cell number
or the signal intensity in the designated channel. p values obtained by two-tailed non-parametric
Student’s t-test, where ** p < 0.005. HSC, hematopoietic stem cell; LT-HSC, long-term reconstituting
hematopoietic stem cell; ST-HSC, short-term reconstituting hematopoietic stem cell; MPP, multipotent
progenitor; HPC, hematopoietic progenitor cell; LMPP, lymphoid-primed multipotent progenitor;
CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte
progenitor; MEP, megakaryocyte-erythrocyte progenitor; Flt3, fms-like tyrosine kinase 3; LSK, Lineage
marker− Sca1+ c-Kit+.
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2.3. Effects of Flt3 Stimulation on the Phosphorylation of Intracellular Ribosomal Protein S6 by HSC and MPP
Murine HSC are thought not to express Flt3 and we identified a small fraction of cells
within the LT-HSC and ST-HSC compartments that express both Flt3 mRNA and Flt3 protein.
To determine whether Flt3+ HSC and MPP respond to Flt3L in vitro, we adapted a previously described
phospho-flow protocol for detecting phosphorylated S6 (pS6) in HSPC, as both the PI3K and RAS
pathways converge to stimulate protein translation via phosphorylation of S6 [16,61–63]. Even though
CD150 staining of whole bone marrow is compromised following cell fixation and permeabilization
with acetone [63], CD150 staining was observed to be maintained within the LSK compartment when
compared to untreated controls (Figure 4A,B). As such, we were able to monitor the levels of pS6 in
the HSC and MPP populations.
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Figure 4. Changes in the phosphorylation of the ribosomal protein S6 in HSC and MPP following
treatment with Flt3 ligand. Representative gating strategies used to analyze phosphorylated ribosomal
protein S6 (pS6) showing: (A) unfixed; and (B) fixed and per eabilized sa ples. Gating of pS6+ HSC
and M P for treated (solid black line) and untreated cells ( otted black line) are shown in (C) and
values for the percentages of positive cells are given in t e text. Shaded histograms depict the isotype
control; (D) The percentag of pS6+ c lls in untreated and treated HSC and MPP; (E) The fold change
in the MFI of pS6 staining in treated HSC and MPP compared to untreated cells. The areas delineated
by solid black boxes in the scatter pl ts and solid black lines in the histograms indicate the population
of cells gat . Dashed arrows point to further gating of these cells. Solid arrows in (A,B,C) indicate
increasing cell number or signal tensity in the designated chann l. Values depicted in (A,B) r present
the percentage of total bone marrows cells within each gate. Data in (D,E) are the mean of the values
obtained from n = 5 mice. p values obtained by wo-tailed non-parametric S udent’s t-test, where
** p < 0.005; . ., on-significant. HSC, hematopoietic stem cell; MPP, multipotent progenitor; Flt3,
fm -like tyrosine kinase 3; Flt3L, flt3 ligand; MFI, mea fluor scence intensity.
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After starvation in serum-free medium, HSC and MPP were stimulated in vitro with 150 ng/mL
Flt3L for 7.5 min before being stained for pS6. For starved MPP stimulated with Flt3L, 63.7 ± 9.2% of
cells expressed pS6 as compared to a value of 10.5 ± 1.38% for starved and untreated MPP (p = 0.0079)
(Figure 4C,D). In contrast, Flt3L treatment resulted in only a marginal increase in the percentage of
HSC expressing pS6 (from 17.1± 5.9% to 20.6± 5.4%, Figure 4C,D). In addition, the mean fluorescence
intensity (MFI) of pS6 staining in starved and treated MPP was increased 3.9 ± 1.4-fold as compared
to the pS6 MFI obtained for starved and untreated MPP, while the corresponding ∆MFI for HSC was
1.2 ± 0.1 (Figure 4E). These data demonstrate that Flt3L stimulates S6 phosphorylation in the majority
of MPP. However, the effect of Flt3L on S6 phosphorylation in HSC is much less pronounced and is
possibly due to the rarity of Flt3+ cells.
2.4. Flt3 Expression Identifies Distinct Sub-Populations of HSC and MPP
Other hematopoietic growth factor receptors, such as the receptors for Epo (EpoR) and M-CSF
(M-CSFR), have been implicated in the pathogenesis of leukemia [64–66]. Both EpoR and M-CSFR
are known to be expressed by HSC, and there is evidence to support their role in the development of
HSC [67,68]. Therefore, we examined whether Flt3 and EpoR or Flt3 and M-CSFR are co-expressed
by cells within the HSC compartment, or if the expression of these receptors identifies distinct
sub-populations of HSC.
To determine if HSC and MPP co-express the genes encoding Flt3 and EpoR, we designed a triplex
qRT-PCR assay to measure the levels of Actb, Flt3 and Epor mRNAs in single cells. The Epor qRT-PCR
assay detected Epor mRNA expression in 0 of 94 CLP and 96 of 98 MEP, suggesting a high degree of
specificity of the assay (Figure 5A). As with cells expressing Actb and Flt3 mRNA, cells expressing
Epor mRNA (EpormRNA+) were readily identified in the HSC and MPP compartments (Figure 5B).
One hundred thirty-six LT-HSC, 139 ST-HSC and 148 MPP were analyzed for expression of Flt3
mRNA and Epor mRNA (Figure 5C). For LT-HSC, 12.8 ± 1.46% of cells were EpormRNA+ and none
of these cells co-expressed both Flt3 and Epor mRNA. Of the ST-HSC analyzed, 19.3 ± 4.6% of cells
expressed Epor mRNA. Notably, 2 of the 139 ST-HSC (1.5 ± 2.5%) analyzed for Flt3 and Epor mRNA
co-expressed both mRNAs. Within the MPP compartment, 8.2 ± 4.6% were EpormRNA+, and none of
them co-expressed Flt3 mRNA. We could not examine the co-expression of Flt3 and EpoR protein at
the cell surface because of the lack of an antibody to EpoR.
We then investigated whether HSC and MPP co-expressed the genes encoding Flt3 and M-CSFR
(Csf1r) and detected very few cells that expressed Csf1r mRNA (Csf1rmRNA+) in these compartments.
Csf1r mRNA was detected in 0.9 ± 0.9% (1 of 122 cells) of LT-HSC, 2.14 ± 1.3% (2 of 118 cells) of
ST-HSC, and 4.8 ± 3.8% (7 of 145 cells) of MPP (Figure 6A). As to the few Csf1rmRNA+ cells, either the
Csf1r qRT-PCR assays was not sensitive enough to detect Csf1r mRNA expression in HSC and MPP or
these cells rarely transcribe the Csf1r gene. Mossadegh-Keller et al. have also investigated whether HSC
express Csf1r mRNA and have reported that very few cells are Csf1rmRNA+, suggesting the latter [68].
Surprisingly, a significant proportion of HSC and MPP expressed M-CSFR protein (Figure 6B,D).
We therefore examined whether cells within the HSC and MPP compartments co-expressed Flt3 and
M-CSFR protein at their surface.
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Figure 5. Flt3 and Epor transcripts are rarely co-expressed by LT-HSC, ST-HSC and MPP. Analysis of
Flt3 and Epor co-expression by LT-HSC, ST-HSC and MPP as carried out using a triplex qRT-PCR assay
specific for Actb, Flt3, and Epor RNA. eactions that i not give rise to a detectable amplification of
Actb were removed from analysis. (A) The percentage of CLP and MEP that expressed Epor mRNA;
(B) the amplification f Epor mRNA in single ST-HSC where ther is a clear distinction b tween
cells that expressed the Epor (shown in red) an those that did not (shown in gre n); and (C) the
percentage of LT-HSC, ST-HSC and MPP that co-expressed both Flt3 and Epor mRNA. The total
fraction of Flt3mRNA+ nd EpormRNA+ are also shown. D ta in (A) ar the mean of the values
obt ined from n = 3 ice. Data in (C) are he mean of the values obtained from n = 3–6 mice. p values
obtained by two-tailed non-param tric Stude t’s t-test, where n.s., non-sig ificant. LT-HSC, long-term
reconstituting hematopoietic stem cell; ST-HSC, short-term reconstituting hematopoietic stem cell;
MPP, multipotent progenitor; MEP, megaka yocyte-erythrocyte pr genitor; CLP, common lymphoid
progenitor; Flt3, fms-like tyrosine kinase 3; Epor, e ythropoietin receptor.
Within the LT-HSC population, 18.6 ± 3.8% of cells were M-CSFR+ and only 1.12 ± 0.48% of
these cells expressed both Flt3 and M-CSFR. M-CSFR was detected at the surface of 23.4 ± 3.6%
of ST-HSC, and 2.8 ± 0.7% co-expressed both Flt3 and M-CSFR protein (Figure 6B). Of the MPP
analyzed, 13.4 ± 2.46% of cells expressed M-CSFR at their surface which was significantly less than
the proportion of M-CSFR+ cells in the ST-HSC population (p = 0.0313), though the fraction of Flt3+
M-CSFR+ MPP (9.9 ± 1.9%) was greater than when compared to the ST-HSC population (p = 0.0313)
(Figure 6B). As Flt3 is only expressed by a small percentage of HSC, we also examined Flt3 and M-CSFR
co-expression as a percentage of Flt3+ cells within the HSC and MPP compartments (Figure 6C). Of the
Flt3+ LT-HSC and Flt3+ ST-HSC, 20.1 ± 6.87% and 34.47 ± 5.35% of cells also expressed M-CSFR,
respectively. Of the Flt3+ MPP population, 14.46 ± 2.62% also expressed M-CSFR at their surface.
These data show that Flt3, EpoR and M-CSFR are selectively expressed during early hematopoiesis
and that expression of these receptors identifies novel subpopulations of early HSPC.
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Figure 6. Flt3 and M-CSFR protein are primarily expressed by distinct sub-populations of LT-HSC
and ST-HSC: (A) analysis of Csf1r mRNA expression by single LT-HSC, ST-HSC and MPP. Data are
the mean of the values obtained from n = 3 mice; (B) the percentage LT-HSC, ST-HSC and MPP that
expressed Flt3, M-CSFR or both of these receptors at their surface; (C) the percentage of Flt3+ LT-HSC,
Flt3+ ST-HSC and Flt3+ MPP that expressed M-CSFR at their surface; and (D) the gating strategy
used to identify M-CSFR+ LT-HSC, M-CSFR+ ST-HSC, and M-CSFR+ MPP (solid black line). Shaded
histograms depict the isotype control. Scatter plots in (E) represent the gating strategy used to identify
HSC that co-expressed Flt3 and M-CSFR at their surface. Isotype controls for both Flt3 and M-CSF
staining within the HSC compartment are also shown. Solid arrows in (D,E) indicate increasing cell
number or signal intensity in the designated channel. Data in (B–D) are the mean of the val es obtained
from n = 6 mice. Values i (D,E) re the perc tages of cells within the corresp nding g tes. p values
wer ob ained by two-tailed non-parametric Student’s t-test, wh re * p < 0.05; n.s., non-significant.
HSC, hematopoi tic stem cell; LT-HSC, long-term reconstitu ing hematopoietic stem cell; ST-HSC,
short-ter rec nstituting hematopoietic stem cell; MPP, multipotent progenitor; Flt3, fms-like tyrosine
kinase 3; M-CSFR, macrophage colony stimulating factor receptor.
3. Discussion
In this study, the expression of Flt3 mRNA and Flt3 protein by the various populations of HSPC
from the murine bone marrow has been investigated. HSC and MPP were then analyzed to determine
whether Flt3 and EpoR or Flt3 and M-CSFR are co-expressed by cells within these compartments.
The findings demonstrate a large degree of heterogeneity within the HSPC compartments, and distinct
sub-populations of HSC and MPP can be identified by their expression of Flt3, EpoR and M-CSFR.
Flt3 is generally considered to be absent from the surf ce of HSC in the adult mouse [5,6,69],
though recent stu ies have identified Flt3 expression within the LSK CD150+ CD48− stem cell
compartment [9,70]. Furthermore, Chu et al. have shown that expression of FLT3-ITD under the
control of the endogenous Flt3 promoter results in the depletion of the murine stem cell pool [70].
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Here, the HSC compartment was divided into LT-HSC (LSK CD150+ CD48− CD34−) and ST-HSC
(LSK CD150+ CD48− CD34+) and both of these populations contain a small percentage of cells
that express Flt3 mRNA and Flt3 protein. Downstream of HSC, Flt3 expression delineates murine
lymphoid/myeloid progenitors from those progressing along the MegE pathway; this is illustrated by
Figure 7, which maps HSPC populations and Flt3 expression to the pairwise model (described in [71]
and [72]). In humans, Flt3 has been reported to be expressed by HSC [73]. Taking these findings
together, the leukemias with Flt3-activating mutations, which include AML and ALL, might well have
arisen from the Flt3+ primitive stem cell compartment of the bone marrow. Therefore, the populations
identified here are important to understanding the origin of leukemia and their potential lineage
affiliation is pertinent to disease progression. This viewpoint is also important to studies that make
use of FLT3-ITD mouse models.
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Figure 7. Heterogeneous expression of lineage affiliated receptors Flt3, EpoR and M-CSFR in murine
HSPC. Four populations of HSC were identified in this study based on the expression of Flt3, EpoR
and M-CSFR (as indicated by the black arrows). These populations are depicted within the shaded area.
MPP and HPC are downstream of HSC (as indicated by the yellow arrow) and are heterogeneous as
to their expression of Flt3, and this is illustrated using the pairwise model (described in [72] and [71]).
The maturation potential of HSPC is depicted by the colored arcs. Expression of Flt3 protein and Flt3
mRNA was strongly associated with lymphoid-GM potential, as expected. Flt3 expression was rarely
observed within the HPC-2 compartment, and was virtually absent from MEP. In this study, HPC-1 and
LMPP were defined as LSK CD48+ CD150− and LSK CD48+ CD150− Flt3hi, respectiv ly. The percentages
of Flt3mRNA+/Flt3+ cells within each compartment are as follows: LT-HSC, 11.6 ± 2.2%/4.6 ± 1%;
ST-HSC, 21 ± 3.4%/7.7 ± 1.2%; MPP, 64 ± 2.2 /63.7 ± 3%; Flt3−/lo HP -1, 57.2 14.1%/58.6 ± 3%;
HP -2, 9.9 ± 6.0%/9.3 ± 1.1 ; L P, 92.8 ± 2.0%/100%; CLP, 66.2 3.8%/80 ± 2.1%; MP,
24.9± 5.4%/36.8± 1.4%; GMP, 21.4± 2.8%/15.7± 0.9%; MEP, 1± 1%/0.5± 0.06%. HSC, hematopoietic
stem cell; LT-HSC, long-term reconstituting hematopoietic stem cell; ST-HSC, short-term reconstituting
hematopoietic stem cell; HPC, hematopoietic progenitor cell; MPP, multipotent progenitor; LMPP,
lymphoid-primed multipotent progenitor; CLP, common lymphoid progenitor; CMP, common myeloid
progenitor; GMP, granulocyte-macrophage progenitor; MEP, megakaryocyte-erythrocyte progenitor; Flt3,
fms-like tyrosine kinase 3; M-CSFR, macrophage colony-stimulating factor receptor; EpoR, erythropoietin
receptor; LSK, Lineage marker− Sca1+ c-Kit+.
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Previous characterization of Flt3+ cells within the primitive cell compartments of the adult
murine bone marrow has indicated that these cells have limited self-renewal capacity [5,7,9]. Indeed,
Flt3 expression within the HSC compartment correlates with a low level of CD150 at the cell
surface (Figure 3D,E) which is associated with a reduced self-renewal ability [59,60]. However,
the reconstitution assays performed in the above studies are limited by their use of bulk Flt3+ LSK cells,
which contain very few cells that are Flt3+ LSK CD150+ CD48−, and their assessment of self-renewal
capacity by just monitoring myeloid reconstitution. Using their FlkSwitch model, the Forsberg group
have recently identified a transient population of fetal Flt3+ HSC that preferentially give rise to
lymphoid cells [74]. Like the Flt3+ cells in the adult murine HSC compartment identified here, fetal
Flt3+ HSC express a low level of CD150 at their surface. Hence, Flt3 expression in the adult HSC
compartment may identify a rare population of lymphoid-biased HSC. Fetal Flt3+ HSC do not persist
in the bone marrow past 8 weeks of age, so it is unlikely that the phenotypic Flt3+ HSC identified here
are fetal Flt3+ HSC that have persisted into late adulthood [74].
Investigation of the expression of Epor mRNA and M-CSFR protein identified subpopulations
of cells within the LT-HSC, ST-HSC and MPP compartments (Figure 7). Co-expression of Flt3
mRNA and EpoR mRNA was exceedingly rare, indicating that Flt3 and EpoR expression almost
exclusively identify distinct subpopulations of multipotent progenitors. Co-expression of M-CSFR
and Flt3 by early HSPC was more common, which was expected since both Flt3 and M-CSFR are
associated with the development of myelomonocytic progenitors. Conventionally, HSC are thought
to gradually commit to mature cell fates by transitioning through various intermediate progenitor
states. However, long-term reconstituting lineage-biased and lineage-restricted progenitors have been
identified in the HSC compartment of the mouse bone marrow [59,60,75–83], and megakaryocyte
specification occurs primarily within the HSC compartment in humans [84]. These findings suggest
that lineage specification occurs at a very early stage of hematopoiesis, without HSC having to
transit through a succession of intermediate progenitors. Indeed, a recent study of human HSPC
supports this viewpoint [85]. The expression of lineage-associated growth factor receptors by HSC
might represent adoption of a fate, providing a selective advantage to cells as to the presence of
a particular growth factor. Some hematopoietic growth factor receptors, including Flt3 and M-CSFR,
have been used to identify lineage-biased subpopulations within currently defined HPC [83,86–89],
and therefore, as already stated in regard to Flt3 expression, EpoR and M-CSFR might be used to
enrich for functionally distinct HSC.
As has been previously reported, Flt3 expression dramatically increases during the HSC-to-MPP
transition. Approximately 60% of MPP (LSK CD150− CD48−) express Flt3 and phosphorylate S6
following stimulation with Flt3L [55]. Progenitors downstream of HSC and MPP, other than the MEP,
were also found to be heterogeneous as to their expression of Flt3 (Figure 7); the patterns reported
here are largely similar to previously published data [55,56,87,90]. As mentioned above, growth factor
receptor expression has been used to identify lineage-biased subpopulations of HPC. Further study of
the populations identified here might be useful in resolving whether progenitor populations that are
viewed as having a number of different lineage options are a uniform population of cells or a mixture
of cells with individual lineage potentials.
As expected, Flt3 expression is linked to populations that have robust lymphoid, granulocyte and
myelomonocytic potential. Conversely, the frequency of Flt3 expression decreases as cells differentiate
towards a MegE fate. This is typified by HPC-1 (LSK CD150− CD48+), which includes the Flt3−/lo
HPC-1 and LMPP populations analyzed in this study, and HPC-2 (LSK CD150+ CD48+). The HPC-1
compartment contains progenitors that preferentially give rise to lymphoid cells and possess limited
MegE potential, and Flt3 expression was most commonly detected within this compartment [55].
HPC-2 have significant myeloid potential and a reduced lymphoid potential when compared to HPC-1,
and Flt3 expression was infrequently detected in the HPC-2 compartment [55]. The importance of Flt3
expression by lymphoid and GM lineages, as opposed to MegE lineage, is emphasized by the findings
from Flt3L-Tg mice [38].
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The findings described here, and in a number of other studies, demonstrate the heterogeneity
of HSPC. Similarly, compartments that were once thought to comprise of a uniform population
of cells have been shown to contain a mixture of cells with varying lineage potentials and
cell-intrinsic states [84–86,91]. Moreover, HSC at different stages of the cell cycle display functional
heterogeneity [92,93], and hematopoietic progenitors fluctuate between states with differing capacities
for particular cell fates [94], highlighting the dynamic nature of cells. These matters need to be
considered when using techniques that are reliant on cell surface phenotypes which only provide
information about a cell at a single moment in time. In this regard, single cell fate mapping and
imaging techniques will be integral to the functional characterization of distinct HSPC subpopulations,
such as those identified in this study. Such work is of importance for our understanding of malignant
transformation in hematopoiesis and the heterogeneity of leukemia.
4. Materials and Methods
4.1. Animals
Male C57/BL6 mice were purchased from Harlan Laboratories, UK, and housed in the Biomedical
Services Unit at The University of Birmingham, UK. All mice were treated in accordance with Home
Office guidelines, and were culled by cervical dislocation between 8–14 weeks of age. The use of
bone marrow cells from normal mice was conducted under a licence provided to Ciaran Mooney
(No. 34942, 18 October 2013) having completed a programme of training approved by the Universities
Accreditation Scheme.
4.2. Flow Cytometry
Bone marrow cells were flushed from mouse tibias, femurs and humeri using flow cytometry
buffer (Dulbecco’s phosphate buffered (DPBS) without Ca+/Mg+ (Thermo Fisher Scientific, Waltham,
MA, USA) which contained 2% fetal calf serum (FCS) (Thermo Fisher Scientific) and 2 mM
ethylenediaminetetraacetic acid (Sigma Aldrich, St. Louis, MO, USA)). Bone marrow cells were
strained using 70 µM Cell strainers (BD biosciences, San Diego, CA, USA) and erythrocytes
were lysed using ACK Lysing Buffer (Thermo Fisher Scientific). Cells were then stained with
fluorescently-labeled antibodies in flow cytometry buffer for 1 h on ice. Other than when CD16/32
expression was examined using fluorescently-labeled antibodies, cells were incubated with purified
anti-CD16/CD32 (clone 93, BioLegend, San Diego, CA, USA) for 20 min to block CD16 (FcγIII)
and CD32 (FcγII) receptors prior to staining. The following antibodies were used to analyze the
phenotype of cells; anti-CD3ε-AF488 (clone 17A2, BioLegend), anti-B220-AF488 (clone RA3-6B2,
BioLegend), anti-CD11b-AF488 (clone M1/70, BioLegend), anti-TER-119-AF488 (clone TER-119,
BioLegend), anti-Ly-6G-AF488 (clone RB6-8C5, BioLegend), anti-CD16/32-PE (clone 93, BioLegend),
anti-CD34-APC (clone RAM34, eBiosciences, San Diego, CA USA), anti-CD48-AF488 (clone HM48-1,
BioLegend), anti-CD48-APC-Cy7 (clone HM48-1, BioLegend), anti-CD115(M-CSFR)-BV421 (cloneAFS98,
BD Biosciences), anti-CD117-PE-CF594 (clone 2B8, BD Biosciences), anti-CD127-PE-Cy7 (clone A7R34,
eBiosciences), anti-CD135-PE (clone A2F10, eBiosciences), anti-CD150-PE (clone TC15-12F12.2, BioLegend),
anti-CD150-Pacific Blue (clone TC15-12F12.2, BioLegend), anti-Sca1-PE-Cy7 (clone D7, eBiosciences),
anti-pS6(Ser235/Ser236)-PE (clone D57.2.2E, Cell Signalling). Data were acquired using a CyAN FACS
Analyser (Beckman Coulter, Fullerton, CA, USA) controlled by Summit v4.3 software.
4.3. Fluorescence Activated Cell Sorting (FACS)
Prior to sorting, stained bone marrow cells were suspended in flow cytometry buffer containing
10% FCS, filtered using Partec CellTrics sterile filters (Sysmex-Partec, Görlitz, Germany) and stored
on ice. All of the HSPC populations were sorted twice to ensure high purity. Cells were sorted into
LightCycler 480 384-well plates (Roche, Basel, Switzerland) for qRT-PCR analysis or into culture
medium for in vitro manipulation. Sorting was carried out using either a MoFlo High Speed
Sorter (Beckman Coulter) controlled by Summit v4.3 software or a MoFlo Astrios (Beckman Coulter)
controlled by Summit v6.2.3 software.
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4.4. Single Cell Quantitative Reverse Transcription Polymerase Chain Reaction
Single cells were sorted into the wells of LightCycler 480 384-well plates (Roche) containing 1µL
of UltraPure DNase/RNase-Free Distilled Water (Thermo Fisher Scientific) for lysis. Gene expression
analysis was carried out using a one-step QuantiTect Multiplex RT-PCR Kit (Qiagen, Hilden, Germany)
containing limiting concentrations of primers and hydrolysis probes specific for the Actb and
Flt3 transcripts. qRT-PCR reactions were carried out and analyzed on a LC480 II instrument
(Roche). The program used for qRT-PCR was as follows: reverse transcription, 50 ◦C for 20 min;
polymerase activation, 95 ◦C for 15 min; and 40–50 cycling steps of denaturation at 95 ◦C for
45 s, and annealing/extension at 60 ◦C for 45 s. Oligonucleotides used for qRT-PCR analysis were
purchased from Biosearch Technologies (Novato, California, USA) and were as follows; Actb forward
primer, 5′-CAGCTTCTTTGCAGCTCCTTC-3′; Actb reverse primer, 5′-CGACCAGCGCAGCGATAT-3′;
Actb hydrolysis probe, 5′-CACCAGTTCGCCATGGA-3′; Flt3 forward primer, 5′-ATCAGCGGGAAAG
CCATCATC-3′; Flt3 reverse primer, 5′-GGGCACACTGGAGGTCTTCT-3′; Flt3 hydrolysis probe,
5′-TCCTCGCACCATTCGGTA-3′; Epor forward primer, 5′- GCAGGAGGGACACAAAGGGT-3′;
Epor reverse primer, 5′- GGGCTCAGACCAGGCACT-3′; Epor hydrolysis probe, 5′-CTCGAACAGCG
AAGGTGTAGCGC-3′; Csf1r forward primer, 5′-ACCTGTCCTGGTCATCACT-3′; Csf1r reverse
primer, 5′-AACCTCTTGGGAGCCTGTACTCAC-3′; Csf1r hydrolysis probe, 5′-GCATAGCCTCGGCC
TTCCTT-3′.
4.5. Phospho-Flow Analysis
Bone marrow cells were stained to identify LT-HSC, ST-HSC and MPP and then washed using
serum-free DPBS (without Ca+/Mg+) three times before being starved in serum-free Iscove’s Modified
Dulbecco’s Medium (Thermo Fisher Scientific) for 3 h. After the starvation period, each sample was
divided in half and one half was stimulated with 150 ng/mL Flt3L for 7.5 min. All samples were then
promptly fixed in 1.6% EM-grade paraformaldehyde (PFA) (VWR International, Radnor, PA, USA) for
15 min. Cells were then permeabilized using ice-cold acetone for 15 min at−20 ◦C, and then stained using
an anti-pS6(Ser235/Ser236)-PE (clone D57.2.2E, Cell Signaling Technology, Danvers, MA, USA) and in
DPBS containing 2% FCS for 1 h on ice. Cells were washed twice with DPBS containing 2% FCS before data
acquisition on a CyAN FACS Analyser (Beckman Coulter) controlled by Summit v4.3 software. During
analysis, pS6 staining of stimulated and unstimulated samples of cells from a single mouse was compared.
5. Conclusions
Analyses of single cells within the HSC and HPC bone marrow compartment of C57/BL6 mice,
by multiplex RT-PCR for mRNA and flow cytometry for surface protein, has revealed that these cells
are heterogeneous in regard to expression of Flt3. Analysis of M-CSFR and EpoR expression within the
multipotent compartments of the bone marrow cells revealed further heterogeneity. Flt3 and EpoR are
rarely co-expressed whereas co-expression of Flt3 and M-CSFR occurs more commonly. The expression
of these receptors for lineage-associated growth factors by HSC indicates their affiliation to or adoption
of a fate. The distinct subpopulations of HSPC identified are important to understanding the disease
origin and heterogeneity of leukemia.
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